Variant Bio Launches Inference, the World’s First Agentic AI Genomic Drug Discovery Platform

Variant Bio announced the launch of Inference on January 6, 2026, described as the world's first agentic AI genomic drug discovery platform.1 2

The platform integrates proprietary and public genetic/multi-omic data, processing hundreds of billions of genetic associations from tens of thousands of genome-wide association studies.1 2 3

Key AI features include Inference Agents for autonomous PhD-level analyses using Model Context Protocol (MCP), VB-Predict for molecular disease models, and VB-Atlas for gene-phenotype mappings.1 2

Built over seven years with over $100 million investment, it's now available to pharmaceutical partners, powering collaborations over $200 million.1 2

Supports secure upload of proprietary data and includes a benefit-sharing pledge for research communities.1 2

Underpins internal drug programs and partnerships, including a new kidney disease collaboration with Boehringer Ingelheim.3 4 7